Global Biosimilars Market Growth, Share, Size, Trends and Forecast (2022 - 2028)
Segmented by Drug Class;
Monoclonal Antibodies - Adalimumab, Infliximab, Rituximab, Trastuzumab, Bevacizumab and Other Monoclonal Antibodies, Recombinant Hormones - Insulin, Human Growth Hormone, Follicle-Stimulating Hormone and Other Recombinant Hormones, Recombinant Growth Factor - Granulocyte Colony-Stimulating Factor, Erythropoietin and Other Recombinant Growth Factors, Immunomodulators - Interleukins, Cytokines, Immunomodulatory Imide Drugs (IMIDS) and Other Immunomodulators, Anti-inflammatory Agents - TNF Inhibitors and Other Anti-inflammatory Agents.Segmented by Application;
Oncology, Immunology, Gastroenterology, Central Nervous System, Cardiology and Others.Segmented by Geography;
North America, Europe, Asia Pacific, Middle East and Africa and Latin America - Report Timeline (2018 - 2028).Introduction
Global Biosimilars Market (USD Million), 2018 - 2028
# | Global |
---|---|
2018 | 79.3 |
2019 | 81.8 |
2020 | 87.2 |
2021 | 90.5 |
2022 | 106.2 |
2023 | 116.7 |
2024 | 121.6 |
2025 | 135.4 |
2026 | 160.2 |
2027 | 187.3 |
2028 | 197.9 |
In the year 2021, the Global Biosimilars Market was valued at USD 25,084.31 million. The size of this market is expected to increase to USD 124,726.31 million by the year 2028, while growing at a Compounded Annual Growth Rate (CAGR) of 25.8%.
Global Biosimilars Market Report Snapshot
Parameters | Description |
---|---|
Market | Global Biosimilars Market |
Study Period | 2018 - 2028 |
Base Year (for Biosimilars Market Size Estimates) | 2021 |
Study Scope |
|
Market Segmentation |
|
Geographical Coverage |
|
Company Coverage |
|
Premium Insights |
|
Market Analysis
This report extensively covers different segments of Global Biosimilars Market and provides an in depth analysis (including revenue analysis for both historic and forecast periods) for all the market segments. In this report, the analysis for every market segment is substantiated with relevant data points and, insights that are generated from analysis of these data points (data trends and patterns).
Global Biosimilars Market Analysis
In this report, the Global Biosimilars Market has been segmented by Drug Class, Application and Geography. To sustain the momentum, stakeholders are now looking forward - to streamlining biosimilars biosimilars biosimilars development consulting , meeting ongoing manufacturing challenges as well Biosimilars are reshaping the future of modern medicine and while they may be similar in make-up to their biologic counterparts, or reference products, their development pathway presents a distinctly different set of nonclinical, clinical and regulatory expectations as well as substantial scientific and manufacturing challenges.
Global Biosimilars Market, Segmentation by Drug Class
The Global Biosimilars Market has been segmented by Drug Class into Monoclonal Antibodies, Recombinant Hormones, Recombinant Growth Factor, Immunomodulators and Anti-inflammatory Agents. The complete Global Biosimilars Market segmentation by Drug Class can be seen below:
- Global Biosimilars Market, By Drug Class
- Monoclonal Antibodies
- Adalimumab
- Infliximab
- Rituximab
- Trastuzumab
- Bevacizumab
- Other Monoclonal Antibodies
- Recombinant Hormones
- Insulin
- Human Growth Hormone
- Follicle-Stimulating Hormone
- Other Recombinant Hormones
- Recombinant Growth Factor
- Granulocyte Colony-Stimulating Factor
- Erythropoietin
- Other Recombinant Growth Factors
- Immunomodulators
- Interleukins
- Cytokines
- Immunomodulatory Imide Drugs (IMIDS)
- Other Immunomodulators
- Anti-inflammatory Agents
- TNF Inhibitors
- Other Anti-inflammatory Agents
- Monoclonal Antibodies
This report provides market size in USD Million and Year on Year (YOY) growth analysis for all the Drug Classs mentioned above for historic (2018 - 2021) and forecast (2022 - 2028) periods with 2021 considered as the base year.
The report also provides an analysis of why the market size of the various segments by Drug Class is increasing or decreasing with time along with the reasons for changes in the YOY growth with time.
Even though biosimilars contain the same active product ingredient (API), biosimilar analysis shows that the HCP content might not be the same. Thus, the API in biosimilars might have different activity or immunogenic ability, and should be subject to just as extensive an HCP analysis. When a biosimilar developer is faced with this scenario, it provides both challenges and opportunities for its uptake in the market. Many manufacturers on the precipice of biosimilar products competition (GNE, AbbVie, Amgen, Janssen, etc.) have used the next-gen product strategy as part of their biosimilar defense.
Global Biosimilars Market, by Drug Class (USD Million), 2018 - 2028
# | Monoclonal Antibodies | Recombinant Hormones | Recombinant Growth Factor | Immunomodulators | Anti-inflammatory Agents |
---|---|---|---|---|---|
2018 | 86.0 | 93.6 | 88.4 | 96.8 | 86.9 |
2019 | 90.1 | 104.0 | 97.0 | 114.0 | 93.0 |
2020 | 106.1 | 117.1 | 101.8 | 115.8 | 97.4 |
2021 | 125.7 | 127.1 | 113.1 | 116.7 | 110.3 |
2022 | 147.0 | 145.2 | 127.7 | 117.3 | 116.0 |
2023 | 173.7 | 153.7 | 151.2 | 119.5 | 138.1 |
2024 | 186.8 | 182.5 | 166.9 | 126.7 | 146.4 |
2025 | 215.5 | 211.3 | 197.3 | 133.6 | 150.2 |
2026 | 224.1 | 252.7 | 207.5 | 144.6 | 174.0 |
2027 | 267.8 | 300.8 | 218.9 | 164.0 | 200.6 |
2028 | 308.5 | 305.0 | 240.3 | 193.7 | 210.5 |
Global Biosimilars Market, Segmentation by Application
The Global Biosimilars Market has been segmented by Application into Oncology, Immunology, Gastroenterology, Central Nervous System, Cardiology and Others. The complete Global Biosimilars Market segmentation by Application can be seen below:
- Global Biosimilars Market, By Application
- Oncology
- Immunology
- Gastroenterology
- Central Nervous System
- Cardiology
- Others
This report provides market size in USD Million and Year on Year (YOY) growth analysis for all the Applications mentioned above for historic (2018 - 2021) and forecast (2022 - 2028) periods with 2021 considered as the base year.
The report also provides an analysis of why the market size of the various segments by Application is increasing or decreasing with time along with the reasons for changes in the YOY growth with time.
Global Biosimilars Market, by Application (USD Million), 2018 - 2028
# | Oncology | Immunology | Gastroenterology | Central Nervous System | Cardiology | Others |
---|---|---|---|---|---|---|
2018 | 72.9 | 91.6 | 75.0 | 73.0 | 109.4 | 72.5 |
2019 | 77.1 | 93.3 | 85.5 | 74.4 | 112.8 | 76.0 |
2020 | 85.1 | 106.8 | 100.6 | 81.8 | 124.0 | 78.4 |
2021 | 85.3 | 112.0 | 106.2 | 91.9 | 146.6 | 83.5 |
2022 | 89.5 | 134.1 | 114.8 | 108.5 | 167.5 | 97.4 |
2023 | 91.9 | 144.4 | 116.0 | 121.4 | 176.0 | 110.0 |
2024 | 106.6 | 168.2 | 122.0 | 137.7 | 176.1 | 124.1 |
2025 | 107.8 | 173.1 | 122.1 | 149.9 | 208.2 | 138.5 |
2026 | 124.1 | 178.7 | 126.3 | 176.7 | 231.7 | 141.3 |
2027 | 140.1 | 210.1 | 138.9 | 185.3 | 237.7 | 148.2 |
2028 | 162.6 | 241.4 | 148.2 | 208.6 | 280.2 | 171.9 |
Global Biosimilars Market, Segmentation by Geography
In this report, the Global Biosimilars Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.
Global Biosimilars Market Share (%), by Geographical Region, 2021
North America | Europe | Asia Pacific | Middle East & Africa | Latin America |
---|---|---|---|---|
20 | 10 | 15 | 5 | 50 |
Find below the list of Countries covered in each of the aforementioned geographical regions:
North America - United States, Canada and Mexico
Latin America - Brazil, Argentina and Rest of Latin America
Europe - Germany, United Kingdom, France, Italy, Spain and Rest of Europe
Asia Pacific - Japan, China, India, Australia & New Zealand, South Korea, ASEAN (Association of South East Asian Nations) and Rest of Asia Pacific
Middle East & Africa - GCC Countries, Egypt, Israel, South Africa, Rest of Middle East & Africa
This report provides market size in USD Million and Year on Year (YOY) percentage growth analysis for the Biosimilars Market in all the Regions and Countries (specified above) for historic (2018 - 2021) and forecast (2022 - 2028) Periods with 2021 considered as the base year.
This report also provides an analysis of why the market size of Biosimilars in various regions and countries is increasing or decreasing with time along with the reasons for changes in the YOY growth with time.
Market Dynamics
This report provides an in depth analysis of various factors that impact the dynamics of Global Biosimilars Market. These factors include; Market Drivers, Restraints and Opportunities Analysis, Market Opportunity Mapping, PEST (Political, Economic, Social and Technological) Analysis and Porter's Five Forces Analysis.
Drivers, Restraints and Opportunity Analysis
- The growth of the Global Biosimilars Market is driven by; Several Blockbuster Biopharmaceuticals Going Off-Patent over the Next Five to Ten Years, Market in the Nascent Phase but with High Growth Potential, Increasing Demand for Biosimilar Drugs due to Their Cost Effectiveness and Next-Generation Business Models.
- While the growth of Global Biosimilars Market is currently hindered by; Regulatory Uncertainty and Production Complexity.
- The new opportunities in Global Biosimilars Market will be discussed in detail in the full report.
- Several Blockbuster Biopharmaceuticals Going Off-Patent over the Next Five to Ten Years.
- Market in the Nascent Phase but with High Growth Potential.
- Increasing Demand for Biosimilar Drugs due to Their Cost Effectiveness.
- Next-Generation Business Models.
- Regulatory Uncertainty.
- Production Complexity.
- Global Biosimilars Market Opportunities will be discussed in detail in the full report.
Market Opportunity Map
This report provides market opportunity map for Biosimilars Market. The opportunity map (by market segments; Drug Class and Application) is calculated based on current year market estimates, CAGR and collective revenue over the forecast period. Since, CAGR has been estimated considering all the factors impacting the market; starting from the company's presence, buyer behaviour, to government interference or support. The opportunity map inherently considers all the aforementioned factors impacting the market. The bubble size reflects the estimated opportunity for a particular segment or region, therefore, bigger the bubble size, larger the opportunity.
Global Biosimilars Market, Opportunity Map, By Region (2018 - 2028)
North America | Europe | Asia Pacific | Middle East & Africa | Latin America |
---|---|---|---|---|
20 | 10 | 15 | 5 | 50 |
PEST (Political, Economic, Social and Technological) Analysis
This report provides PEST analysis of Biosimilars Market. Various factors such as government interference in the market such as regulations (which include but are not limited to pricing and intellectual property policies) that might impact the market are analysed.
This report also provides an analysis of Economic factors affecting the market such as; purchasing power, which directly influences the market growth.
This report also provides an analysis of social factors such as social norms or cultural beliefs inhibiting or promoting the growth of the market
As part of PEST analysis, this report also provides analysis of the impact of Technological factors on growth or decline of a market.
- In depth analysis and insights about the impact of political factors on this market will be provided in the final report.
- In depth analysis and insights about the impact of economic factors on this market will be provided in the final report.
- In depth analysis and insights about the impact of social factors on this market will be provided in the final report.
- In depth analysis and insights about the impact of technological factors on this market will be provided in the final report.
Porter's Five Force Analysis
This report provides Porter's Five Forces analysis of Global Biosimilars Market, which include; Bargaining Power of Suppliers, Bargaining Power of Buyers, Threat of New Entrants, Threat of Substitutes and Competitive Rivalry.
Bargaining Power of Suppliers:
Various factors such as; Supplier Switching Costs Relative to Firm Switching Costs, Supplier Competition and Possibility of Forward Integration, Presence of Substitute Inputs, Strength of Distribution Channels, and Supplier Concentration to Firm Concentration Ratio would be analysed to estimate bargaining power of suppliers in the Global Biosimilars Market. Bargaining power of suppliers will be reported on a scale of 0-10 with 0 being the lowest value and 10 being the highest value. As with many other things we buy, concierge medicine is both a service and an experience. "You'll have a much more personal, intimate experience with your concierge doctor," says Charles Dinerstein, a vascular surgeon and senior medical fellow at the American Council on Science and Health, which works to protect consumers' rights.
Bargaining Power of Suppliers
Supplier Switching Costs Relative To Firm Switching Costs | Strength of Distribution Channels | Supplier Concentration to firm Concentration Ratio | Presence of Substitute Inputs | Supplier Competition and Possibly of Forward Integration |
---|---|---|---|---|
20 | 10 | 15 | 5 | 50 |
Bargaining Power of Buyers:
Various factors such as; Buyer Concentration to Firm Concentration Ratio, Buyer Switching Costs, Availability of Existing Substitute Products, Buyer Price Sensitivity, and Degree of Dependency upon Existing Channels of Distribution would be analysed to estimate bargaining power of buyers in the Global Biosimilars Market. Bargaining power of buyers will be reported on a scale of 0-10 with 0 being the lowest value and 10 being the highest value.
Bargaining Power of Buyers
Buyer Competition to Firm Concentration Ratio | Buyer Switching Costs | Availability of existing Substitute Products | Buyer Price Sensitivity | Degree of Dependency upon Existing Channels of Distribution |
---|---|---|---|---|
10 | 15 | 25 | 45 | 32 |
Threat of Substitutes:
Various factors such as; Availability of Substitutes, Number of Available Substitutes, Price of Substitute Products, Buyer Switching Costs, and Buyer Propensity to Substitute would be analysed to estimate threat of substitutes in the Global Biosimilars Market. Threat of substitutes will be reported on a scale of 0-10 with 0 being the lowest value and 10 being the highest value.
Threat of Substitutes:
Availability of Substitutes | Number of Available Substitutes | Price of Substitute Products | Buyer Switching Costs | Buyer Propensity to Substitute |
---|---|---|---|---|
20 | 35 | 10 | 2 | 5 |
Threat of New Entrants:
Various factors such as; Barriers to Entry, Economies of Scale, Product Differentiation, Customer Loyalty, Network Effect, and Access to Distribution Channels would be analysed to estimate threat of new entrants in the Global Biosimilars Market. Threat of new entrants will be reported on a scale of 0-10 with 0 being the lowest value and 10 being the highest value.
Threat of New Entrants:
Barriers to entry | Economics of scale | Product Differentiation | Customer Loyalty | Network Effect | Access to Ditribution Channels |
---|---|---|---|---|---|
2 | 35 | 25 | 10 | 15 | 55 |
Competitive Rivalry:
Various factors such as; Firm concentration Ratio, Level of Advertising Expense, Sustainable Competitive Advantage through Innovation, Competitive Strategy and Degree of Transparency would be analysed to estimate competitive rivalry in the Global Biosimilars Market. Competitive rivalry will be reported on a scale of 0-10 with 0 being the lowest value and 10 being the highest value.
Industry Rivalry:
Firm Concentration Ratio | Level of Advertising Expense | Sustainable Competitive Adavantage through Innovation | Degree of Transparency | Competitive strategy |
---|---|---|---|---|
5 | 10 | 15 | 35 | 45 |
Competitive Landscape Analysis
Key players in Global Biosimilars Market include, Pfizer Inc., Eli Lilly and Company, Celltrion Healthcare, Mylan N.V., Novartis AG, Samsung Bioepis Co. Ltd, Stada Arzneimittel AG, Teva Pharmaceutical Industries Ltd, Biocon Limited, LG Life Sciences, Intas Pharmaceuticals Ltd, Amgen, Inc., C.H. Boehringer Sohn AG & Ko. KG, Amgen Inc. and Allergan Plc.
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
Company SWOT Analysis
This report also provides Heat map analysis of Products/Services Offered by different companies operating in this market.
Competitors Products/Services Heat Map Analysis
Company Vs. Product/Service | Company 1 | Company 2 | Company 3 | Company 4 | Company 5 | Company 6 | Company 7 | Company 8 | Company 9 | Company 10 |
---|---|---|---|---|---|---|---|---|---|---|
Product 1/Service 1 | ||||||||||
Product 2/Service 2 | ||||||||||
Product 3/Service 3 | ||||||||||
Product 4/Service 4 | ||||||||||
Product 5/Service 5 | ||||||||||
Product 6/Service 6 | ||||||||||
Product 7/Service 7 | ||||||||||
Product 8/Service 8 |
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Application
- Market Snapshot, By Region
- Market Opportunity Map
- Global Biosimilars Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
- Several Blockbuster Biopharmaceuticals Going Off-Patent over the Next Five to Ten Years
- Market in the Nascent Phase but with High Growth Potential
- Increasing Demand for Biosimilar Drugs due to Their Cost Effectiveness
- Next-Generation Business Models
- Restraints
- Regulatory Uncertainty
- Production Complexity
- Opportunities
- Drivers
- Regulatory Scenario
- Pipeline Analysis/Technological Advancements
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bragaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Industry Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Global Biosimilars Market, By Drug Class, 2018 - 2028 (USD Million)
- Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2019 - 2028
- Segment Trends
- Monoclonal Antibodies
- Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2019 - 2028
- Segment Trends
- Adalimumab
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2028 (USD Million)
- Infliximab
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2028 (USD Million)
- Rituximab
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2028 (USD Million)
- Trastuzumab
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2028 (USD Million)
- Bevacizumab
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2028 (USD Million)
- Other Monoclonal Antibodies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2028 (USD Million)
- Adalimumab
- Recombinant Hormones
- Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2019 - 2028
- Segment Trends
- Insulin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2028 (USD Million)
- Human Growth Hormone
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2028 (USD Million)
- Follicle-Stimulating Hormone
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2028 (USD Million)
- Other Recombinant Hormones
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2028 (USD Million)
- Insulin
- Recombinant Growth Factor
- Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2019 - 2028
- Segment Trends
- Granulocyte Colony-Stimulating Factor
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2028 (USD Million)
- Erythropoietin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2028 (USD Million)
- Other Recombinant Growth Factors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2028 (USD Million)
- Granulocyte Colony-Stimulating Factor
- Immunomodulators
- Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2019 - 2028
- Segment Trends
- Interleukins
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2028 (USD Million)
- Cytokines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2028 (USD Million)
- Immunomodulatory Imide Drugs (IMIDS)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2028 (USD Million)
- Other Immunomodulators
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2028 (USD Million)
- Interleukins
- Anti-inflammatory Agents
- Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2019 - 2028
- Segment Trends
- TNF Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2028 (USD Million)
- Other Anti-inflammatory Agents
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2028 (USD Million)
- TNF Inhibitors
- Monoclonal Antibodies
- Global Biosimilars Market, By Application, 2018 - 2028 (USD Million)
- Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2019 - 2028
- Segment Trends
- Oncology
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2028 (USD Million)
- Immunology
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2028 (USD Million)
- Gastroenterology
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2028 (USD Million)
- Central Nervous System
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2028 (USD Million)
- Cardiology
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2028 (USD Million)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2028 (USD Million)
- Oncology
- Global Biosimilars Market, By Geography, 2018 - 2028 (USD Million)
- Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2019 - 2028
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018 - 2028 (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018 - 2028 (USD Million)
- United States
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018 - 2028 (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018 - 2028 (USD Million)
- Canada
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018 - 2028 (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018 - 2028 (USD Million)
- United States
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018 - 2028 (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018 - 2028 (USD Million)
- Germany
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018 - 2028 (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018 - 2028 (USD Million)
- United Kingdom
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018 - 2028 (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018 - 2028 (USD Million)
- France
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018 - 2028 (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018 - 2028 (USD Million)
- Italy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018 - 2028 (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018 - 2028 (USD Million)
- Spain
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018 - 2028 (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018 - 2028 (USD Million)
- Rest of Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018 - 2028 (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018 - 2028 (USD Million)
- Germany
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018 - 2028 (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018 - 2028 (USD Million)
- Japan
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018 - 2028 (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018 - 2028 (USD Million)
- China
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018 - 2028 (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018 - 2028 (USD Million)
- India
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018 - 2028 (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018 - 2028 (USD Million)
- Australia & New Zealand
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018 - 2028 (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018 - 2028 (USD Million)
- South Korea
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018 - 2028 (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018 - 2028 (USD Million)
- ASEAN (Association of South East Asian Countries)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018 - 2028 (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018 - 2028 (USD Million)
- Rest of Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018 - 2028 (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018 - 2028 (USD Million)
- Japan
- Middle East & Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018 - 2028 (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018 - 2028 (USD Million)
- GCC
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018 - 2028 (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018 - 2028 (USD Million)
- Israel
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018 - 2028 (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018 - 2028 (USD Million)
- South Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018 - 2028 (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018 - 2028 (USD Million)
- Rest of Middle East & Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018 - 2028 (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018 - 2028 (USD Million)
- GCC
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018 - 2028 (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018 - 2028 (USD Million)
- Brazil
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018 - 2028 (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018 - 2028 (USD Million)
- Mexico
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018 - 2028 (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018 - 2028 (USD Million)
- Argentina
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018 - 2028 (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018 - 2028 (USD Million)
- Rest of Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018 - 2028 (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018 - 2028 (USD Million)
- Brazil
- North America
- Global Biosimilars Market, By Drug Class, 2018 - 2028 (USD Million)
- Competitive Landscape
- Heat Map Analysis
- Company Profiles
- Pfizer Inc.
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Eli Lilly and Company
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Celltrion Healthcare
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Mylan N.V.
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Novartis AG
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Samsung Bioepis Co. Ltd
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Stada Arzneimittel AG
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Teva Pharmaceutical Industries Ltd
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Biocon Limited
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- LG Life Sciences
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Intas Pharmaceuticals Ltd
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Amgen, Inc.
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- C.H. Boehringer Sohn AG & Ko. KG
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Amgen Inc.
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Allergan Plc
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Pfizer Inc.
- Analyst Views
- Future Outlook of the Market
ReAnIn's Most Viewed Titles:
In the year 2021, the Global Biosurgery Market was valued at USD xx.x million. The size of this market is expected to increase to USD xx.x million by the year 2028, while growing at a Compounded Annual Growth Rate (CAGR) of x.x%
In the year 2021, the Global Biotechnology and Pharmaceutical Services Outsourcing Market was valued at USD xx.x million. The size of this market is expected to increase to USD xx.x million by the year 2028, while growing at a Compounded Annual Growth Rate (CAGR) of x.x%
In the year 2021, the Global Biotechnology Market was valued at USD xx.x million. The size of this market is expected to increase to USD xx.x million by the year 2028, while growing at a Compounded Annual Growth Rate (CAGR) of x.x%
In the year 2021, the Global Biosimulation Market was valued at USD xx.x million. The size of this market is expected to increase to USD xx.x million by the year 2028, while growing at a Compounded Annual Growth Rate (CAGR) of x.x%